Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of FOLFIRINOX Combined With the Glycogen Synthase Kinase-3 Beta (GSK-3 β) Inhibitor Elraglusib and the Transforming Growth Factor-β (TGF-β) Inhibitor Losartan in Patients With Untreated Metastatic Pancreatic Adenocarcinoma

NCT05077800 is registered in ClinicalTrials.gov with Colin D. Weekes, M.D., PhD as lead sponsor.

NCT NCT05077800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05077800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of FOLFIRINOX Combined With the Glycogen Synthase Kinase-3 Beta (GSK-3 β) Inhibitor Elraglusib and the Transforming Growth Factor-β (TGF-β) Inhibitor Losartan in Patients With Untreated Metastatic Pancreatic Adenocarcinoma
Lead sponsor
Colin D. Weekes, M.D., PhD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 21, 2022
Completion date
December 31, 2026
Enrollment
70 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma, pancreatic adenocarcinoma metastatic